Advagraf + Prograf

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Heart Transplantation

Conditions

Heart Transplantation, Lung Transplantation, Pancreas (Including SPK) Transplantation

Trial Timeline

Jul 1, 2011 → Nov 1, 2013

NCT ID

NCT01332201

About Advagraf + Prograf

Advagraf + Prograf is a phase 2 stage product being developed by Astellas Pharma for Heart Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT01332201. Target conditions include Heart Transplantation, Lung Transplantation, Pancreas (Including SPK) Transplantation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03216447	Approved	UNKNOWN	Nov 23, 2017	Sep 30, 2025	Liver Transplantation
NCT02251691	Approved	UNKNOWN	May 9, 2014	Mar 31, 2020	Adherence to Medication Regime
NCT02268201	Approved	Terminated	Jul 23, 2013	Mar 31, 2015	Kidney Transplant Recipients
NCT01332201	Phase 2	Completed	Jul 1, 2011	Nov 1, 2013	Heart Transplantation
NCT01742676	Approved	Completed	Apr 1, 2011	Apr 1, 2013	Renal Transplantation

Competing Products

20 competing products in Heart Transplantation

See all competitors

Product	Company	Stage	Hype Score
IV diuretic	Nuwellis	Pre-clinical	15
IV Loop Diuretics	Nuwellis	Pre-clinical	15
Stepped pharmacologic care	Nuwellis	Phase 3	69
IV Loop Diuretics (LD)	Nuwellis	Pre-clinical	15
TRV120027 + Normal Saline	Trevena	Phase 1	25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	44
TRV120027 + Placebo	Trevena	Phase 1/2	33
Ilofotase alfa + Placebo	AM-Pharma	Phase 2	44
INXN-4001	Precigen	Phase 1	28
LY3461767 + Placebo	Eli Lilly	Phase 1	33
SGLT2i, beta blocker, ARNI, MRA, MTD	Eli Lilly	Approved	85
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	52
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks	Daiichi Sankyo	Approved	85
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil	Daiichi Sankyo	Phase 3	77
Olmesartan	Daiichi Sankyo	Phase 3	77
Carperitide + Placebo	Daiichi Sankyo	Phase 2	52
Edoxaban	Daiichi Sankyo	Pre-clinical	23
Regadenoson	Astellas Pharma	Phase 1	33
FK506E	Astellas Pharma	Phase 3	77
Conivaptan	Astellas Pharma	Approved	85

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved